• Direct Mouse Genotyping Kit Plus for SCA3 Studies

  2026-09-22

  The Direct Mouse Genotyping Kit Plus supports rapid mouse tissue lysis and direct PCR template preparation without DNA purification or precipitation. It combines neutralized lysate workflows with a PCR master mix with dye reagents for mouse genotyping assay development, transgene detection in mice, and colony screening.

• YM 58483 (BTP2): A SOCE Assay Strategy

  2026-09-22

  YM 58483 (BTP2) is a versatile SOCE blocker for separating calcium-entry mechanisms from downstream immune and fibrosis phenotypes. This article translates ORAI2 pathway findings into practical assay design, controls, and interpretation strategies.

• Epinephrine Bitartrate: A Hemodynamic Assay Lens

  2026-09-21

  Epinephrine Bitartrate is a non-selective adrenergic receptor agonist whose effects depend on receptor balance, tissue state, and assay timing. This article presents a state-aware framework for interpreting cardiovascular, airway, and neurobiology experiments without confusing receptor potency with system-level hemodynamics.

• PPARγ, Macrophage Polarization, and DSS-Induced IBD

  2026-09-21

  The reference study identifies a PPARγ–STAT-1/STAT-6 axis that links macrophage polarization with disease severity in a dextran sulfate sodium model of inflammatory bowel disease. Its combined cell and mouse experiments suggest that PPARγ activation suppresses proinflammatory M1 features, promotes M2-associated markers, and improves intestinal barrier injury, while also defining important limits for translation beyond the model.

• Cy3 Goat Anti-Human IgG (H+L) Guide

  2026-09-20

  The Cy3 Goat Anti-Human IgG (H+L) Antibody is a Cy3 conjugated secondary antibody for detecting human immunoglobulins in immunofluorescence, immunohistochemistry, flow cytometry, and ELISA. Its defined fluorescence, affinity purification, and storage formulation support flexible human IgG detection, but the reagent does not establish antiviral neutralization.

• SR-202: PPARγ Antagonism in Translational Research

  2026-09-19

  A mechanism-first analysis of SR-202 as a selective PPARγ antagonist for insulin resistance research, obesity biology, adipocyte differentiation, and immunometabolic pathway validation.

• Carbapenemase Spread in CREC: Guangdong Study

  2026-09-18

  Chen et al. integrate gene localization, antimicrobial susceptibility testing, conjugation, mobile-element analysis, and genotyping to examine carbapenemase-encoding genes in carbapenem-resistant Enterobacter cloacae across eight teaching hospitals. The findings emphasize the predominance and transferability of plasmid-associated blaNDM-1, while also showing why in vitro transfer results should be interpreted separately from direct hospital transmission.

• Cyclic Pifithrin-α hydrobromide Workflows

  2026-09-18

  Use Cyclic Pifithrin-α hydrobromide to separate p53-dependent stress responses from broader DNA-damage and neuroinflammatory biology. This workflow combines apoptosis, irradiation, and trigeminal pain assays while emphasizing controls that prevent overinterpreting cross-domain results.

• Direct Mouse Genotyping Kit Plus for Macrophage Models

  2026-09-17

  The Direct Mouse Genotyping Kit Plus turns small mouse tissue samples into direct-PCR templates, helping laboratories verify lineage-tracing, reporter, transgenic, and knockout alleles with fewer purification steps. Its dye-containing high-fidelity master mix also simplifies post-PCR gel analysis, while practical controls and troubleshooting guidance help distinguish true genotype calls from lysate or primer artifacts.

• Meropenem Trihydrate: From Mechanism to Translation

  2026-09-17

  A translational framework for using Meropenem trihydrate to connect β-lactam mechanism, resistance phenotyping, metabolomics, and infection-model design without overstating what any single assay can prove.

• 12-O-tetradecanoyl phorbol-13-acetate: PKC/ERK Workflows

  2026-09-16

  TPA provides a rapid, controllable perturbation for dissecting protein kinase C signaling and ERK/MAPK pathway activation in cells, biochemical assays, and approved skin cancer model workflows. This guide emphasizes time-resolved experimental design, practical controls, formulation, and troubleshooting rather than treating TPA as a pathway-specific therapeutic surrogate.

• SU5416 (Semaxanib): VEGFR2 Angiogenesis Research

  2026-09-16

  SU5416, also called Semaxanib, is a selective VEGFR2 tyrosine kinase inhibitor used to study VEGF-induced angiogenesis inhibition and tumor vascularization suppression. Product data also describe SU5416 as an aryl hydrocarbon receptor (AHR) agonist, while vascular-cell research on BCKA-driven HIF1α activation provides a separate metabolic context rather than direct evidence for SU5416.

• PreScission Protease (PSP): Tag Cleavage Guide

  2026-09-15

  PreScission Protease (PSP) is a recombinant HRV 3C protease fusion enzyme for removing compatible affinity tags from recombinant proteins while supporting recovery of the target protein. It should be used only when the required recognition sequence is present and accessible; it is not a general-purpose protease for broad proteolysis or non-canonical cleavage sites.

• NADPH Oxidase ROS and Arterial Contraction

  2026-09-15

  The reference study identifies L-type voltage-gated Ca2+ channels as the principal downstream route by which NADPH oxidase-derived reactive oxygen species promote contraction in saphenous arteries from early postnatal rats. Its inhibitor-interaction design separates this mechanism from Rho-kinase, PKC, and Src-kinase signaling, providing a useful framework for interpreting kinase controls in vascular experiments.

• Testosterone Bounce in Degarelix-Treated Prostate Cancer

  2026-09-14

  A retrospective study identified testosterone bounce—recovery above 20 ng/dL after achieving a lower nadir—as a prognostic marker associated with longer overall and cancer-specific survival in degarelix-treated prostate cancer. The finding supports longitudinal testosterone monitoring alongside PSA, while the absence of an observed progression-free survival association argues against using testosterone bounce as a standalone treatment-response endpoint.

8125 records 1/542 page Next 12345 下5页 Last page